Department of Gynecology, First Affiliated Hospital of China Medical University, Liaoning, China.
Gynecol Oncol. 2010 Mar;116(3):563-71. doi: 10.1016/j.ygyno.2009.11.015.
To determine the clinicopathological significance of RhoC expression in human ovarian cancer and its effect on the expression of vascular endothelial growth factor (VEGF), Rho-associated coiled-coil-forming kinase (ROCK), and metal matrix proteinases (MMPs).
Tissue samples from normal ovaries, benign ovarian tumors, and epithelial ovarian cancer were collected. The mRNA and protein expression levels of RhoC, ROCK-I, VEGF, and MMP9 were assessed using reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot, and compared to the clinicopathological characteristics of the sample of origin using the Pearson method of correlation analysis. Small interfering RNA (siRNA) was also used to target RhoC expression in the OVCAR3 and CaOV3 ovarian cancer cell lines, after which cell invasion and migration assays were performed, and the expression of ROCK-I, VEGF, and MMP9 was evaluated.
The expression levels of RhoC, ROCK-I, VEGF, and MMP9 mRNA and protein were significantly higher in ovarian cancer, showing a correlation with clinical stage but not histological type. RhoC expression was positively correlated with ROCK-I, VEGF, and MMP9 expression. Decreased RhoC expression in siRNA-targeted cells inhibited their ability to invade and migrate, as well as inhibiting ROCK-I, VEGF, and MMP9 expression.
The expression level of RhoC is correlated to clinical stage and vascularization in ovarian cancer.
确定 RhoC 在人卵巢癌中的表达与临床病理意义及其对血管内皮生长因子（VEGF）、Rho 相关卷曲螺旋形成激酶（ROCK）和金属基质蛋白酶（MMPs）表达的影响。
收集正常卵巢、良性卵巢肿瘤和上皮性卵巢癌组织标本。采用逆转录聚合酶链反应（RT-PCR）和 Western blot 检测 RhoC、ROCK-I、VEGF 和 MMP9 的 mRNA 和蛋白表达水平，并采用 Pearson 相关分析方法与样本的临床病理特征进行比较。采用小干扰 RNA（siRNA）靶向 RhoC 在 OVCAR3 和 CaOV3 卵巢癌细胞系中的表达，然后进行细胞侵袭和迁移实验，并评估 ROCK-I、VEGF 和 MMP9 的表达。
RhoC、ROCK-I、VEGF 和 MMP9 的 mRNA 和蛋白表达水平在卵巢癌中明显升高，与临床分期相关，但与组织学类型无关。RhoC 表达与 ROCK-I、VEGF 和 MMP9 表达呈正相关。siRNA 靶向 RhoC 表达降低可抑制细胞侵袭和迁移能力，并抑制 ROCK-I、VEGF 和 MMP9 表达。
RhoC 在卵巢癌中的表达水平与临床分期和血管生成有关。
